Vreman Hendrik J, Wong Ronald J, Stevenson David K
Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, Stanford, CA 94305-5208, USA.
Semin Perinatol. 2004 Oct;28(5):326-33. doi: 10.1053/j.semperi.2004.09.003.
Phototherapy is the most common therapeutic intervention used for the treatment of hyperbilirubinemia. Although it has become a mainstay since its introduction in 1958, a better understanding of the photobiology of bilirubin, characteristics of the phototherapy devices, the efficacy and safety considerations of phototherapy applications, and improvements in spectroradiometers and phototherapy devices are necessary for more predictable and improved clinical practices and outcomes. A step forward in instituting consistent, uniform, and effective use of phototherapy is the recent American Academy of Pediatrics clinical guideline on the management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation, which outlines a clinical strategy for the diagnosis of hyperbilirubinemia and contains direct recommendations for the application of phototherapy. This article reviews the parameters that determine the efficacy of phototherapy, briefly discusses current devices and methods used to deliver phototherapy, and speculates on future directions and studies that are still needed to complement our presently incomplete knowledge of the facets of this common mode of therapy.
光疗是治疗高胆红素血症最常用的治疗干预措施。自1958年引入以来,它已成为一种主要手段,但为了实现更可预测和更好的临床实践及结果,有必要更深入地了解胆红素的光生物学、光疗设备的特性、光疗应用的疗效和安全性考量,以及光谱辐射计和光疗设备的改进。在实现光疗的一致、统一和有效使用方面向前迈进的一步是美国儿科学会最近发布的关于孕35周及以上新生儿高胆红素血症管理的临床指南,该指南概述了高胆红素血症的诊断临床策略,并包含光疗应用的直接建议。本文回顾了决定光疗疗效的参数,简要讨论了当前用于实施光疗的设备和方法,并推测了未来仍需开展的方向和研究,以补充我们目前对这种常见治疗方式各方面尚不完整的认识。